Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 18


Distinct sets of FGF receptors sculpt excitatory and inhibitory synaptogenesis.

Dabrowski A, Terauchi A, Strong C, Umemori H.

Development. 2015 May 15;142(10):1818-30. doi: 10.1242/dev.115568. Epub 2015 Apr 29.


The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.

Ganguly SS, Li X, Miranti CK.

Front Oncol. 2014 Dec 15;4:364. doi: 10.3389/fonc.2014.00364. eCollection 2014. Review.


FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Carstens JL, Shahi P, Van Tsang S, Smith B, Creighton CJ, Zhang Y, Seamans A, Seethammagari M, Vedula I, Levitt JM, Ittmann MM, Rowley DR, Spencer DM.

Cancer Res. 2014 Jan 15;74(2):609-20. doi: 10.1158/0008-5472.CAN-13-1093. Epub 2013 Dec 4.


Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.

Pascal LE, Ai J, Masoodi KZ, Wang Y, Wang D, Eisermann K, Rigatti LH, O'Malley KJ, Ma HM, Wang X, Dar JA, Parwani AV, Simons BW, Ittman MM, Li L, Davies BJ, Wang Z.

PLoS One. 2013 Nov 18;8(11):e79542. doi: 10.1371/journal.pone.0079542. eCollection 2013.


Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD.

Cancer Res. 2013 May 1;73(9):2718-36. doi: 10.1158/0008-5472.CAN-12-4213. Epub 2013 Apr 22.


Current mouse and cell models in prostate cancer research.

Wu X, Gong S, Roy-Burman P, Lee P, Culig Z.

Endocr Relat Cancer. 2013 Jun 24;20(4):R155-70. doi: 10.1530/ERC-12-0285. Print 2013 Aug. Review.


FGFR1 is essential for prostate cancer progression and metastasis.

Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, Wang F, Rowley DR.

Cancer Res. 2013 Jun 15;73(12):3716-24. doi: 10.1158/0008-5472.CAN-12-3274. Epub 2013 Apr 10.


Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.

Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y, Perez M, Muñoz-Galvan S, Cañamero M, Renner O, Carnero A.

PLoS One. 2013;8(4):e60277. doi: 10.1371/journal.pone.0060277. Epub 2013 Apr 2. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/1b8b6002-4e0f-4c5d-8ae8-fd45447b6149. Renner, Oliver [added].


Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Irshad S, Abate-Shen C.

Cancer Metastasis Rev. 2013 Jun;32(1-2):109-22. doi: 10.1007/s10555-012-9409-1. Review.


A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.

di Martino E, Tomlinson DC, Knowles MA.

Adv Urol. 2012;2012:429213. doi: 10.1155/2012/429213. Epub 2012 Jul 31.


Mouse models of prostate cancer.

Valkenburg KC, Williams BO.

Prostate Cancer. 2011;2011:895238. doi: 10.1155/2011/895238. Epub 2011 Feb 23.


Differential transformation capacity of Src family kinases during the initiation of prostate cancer.

Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6579-84. doi: 10.1073/pnas.1103904108. Epub 2011 Apr 4.


Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.

Elo TD, Valve EM, Seppänen JA, Vuorikoski HJ, Mäkelä SI, Poutanen M, Kujala PM, Härkönen PL.

Neoplasia. 2010 Nov;12(11):915-27.


FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A.

Cancer Res. 2010 Mar 1;70(5):2085-94. doi: 10.1158/0008-5472.CAN-09-3746. Epub 2010 Feb 23.


Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.

Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA.

Cancer Res. 2009 Jun 1;69(11):4613-20. doi: 10.1158/0008-5472.CAN-08-2816. Epub 2009 May 19.


Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.

FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA.

Prostate Cancer Prostatic Dis. 2009;12(2):192-7. doi: 10.1038/pcan.2008.46. Epub 2008 Sep 2.


Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.

Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON.

Cancer Cell. 2007 Dec;12(6):572-85.


A time- and dose-dependent STAT1 expression system.

Leitner NR, Strobl B, Bokor M, Painz R, Kolbe T, Rülicke T, Müller M, Karaghiosoff M.

BMC Biotechnol. 2006 Dec 21;6:48.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk